Expansion and shrinkage of central nervous system tumor coinciding with human growth hormone therapy: Case report

Matthew H. Connors, James E. Boggan, Brian Chong, Sobha Kollipara

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

OBJECTIVE AND IMPORTANCE: The influence of human growth hormone (hGH) therapy on the recurrence rates of childhood central nervous system tumors is controversial. Because growth hormone has the ability to increase cell proliferation, it is recommended that hGH therapy wait until central nervous system lesions are inactive and antitumor therapy complete, usually 1 to 2 years. CLINICAL PRESENTATION: We report the enlargement and decrease in size of a hypothalamic pilocytic astrocytoma in a 12-year-old boy after two trials of hGH. Partial resection and radiation of the tumor were performed at 3 years of age, with no change noted over the next 9 years. His height was less than the 5th centile with midparental height at the 90th to 95th centiles. Growth velocity was 3.3 cm/yr. Bone age was normal and there were no signs of puberty. There was no GH response to clonidine and L-dopa testing. INTERVENTION: Volume measurements were performed on gadolinium enhanced tumor images. Growth rate increased to 11.7 cm and the tumor volume increased 230% over the 12 months of hGH therapy. Significant tumor shrinkage (42%) and growth deceleration occurred within the 3 month interval of stopping hGH. Tumor volume again increased (134%) and decreased (22%) after restarting and then stopping hGH. No evidence of tumor necrosis or alteration in ventricular size was found. The patient was asymptomatic. CONCLUSION: These observations indicate that tumor size change is associated with the metabolic response to hGH therapy. It is unclear whether the volume increase represents altered blood-brain or selective blood-tumor barrier permeability, growth factor receptors, and/or tumor cell growth.

Original languageEnglish (US)
Pages (from-to)1243-1246
Number of pages4
JournalNeurosurgery
Volume39
Issue number6
DOIs
StatePublished - Dec 1996
Externally publishedYes

Fingerprint

Central Nervous System Neoplasms
Human Growth Hormone
Neoplasms
Growth
Tumor Burden
Therapeutics
Deceleration
Growth Factor Receptors
Astrocytoma
Gadolinium
Clonidine
Levodopa
Puberty
Growth Hormone
Permeability
Necrosis
Central Nervous System
Cell Proliferation
Radiation
Bone and Bones

Keywords

  • Astrocytoma
  • Growth
  • Growth hormone
  • Magnetic resonance imaging
  • Tumor growth

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Expansion and shrinkage of central nervous system tumor coinciding with human growth hormone therapy : Case report. / Connors, Matthew H.; Boggan, James E.; Chong, Brian; Kollipara, Sobha.

In: Neurosurgery, Vol. 39, No. 6, 12.1996, p. 1243-1246.

Research output: Contribution to journalArticle

Connors, Matthew H. ; Boggan, James E. ; Chong, Brian ; Kollipara, Sobha. / Expansion and shrinkage of central nervous system tumor coinciding with human growth hormone therapy : Case report. In: Neurosurgery. 1996 ; Vol. 39, No. 6. pp. 1243-1246.
@article{98ed85096b994afd98902e702437ef5d,
title = "Expansion and shrinkage of central nervous system tumor coinciding with human growth hormone therapy: Case report",
abstract = "OBJECTIVE AND IMPORTANCE: The influence of human growth hormone (hGH) therapy on the recurrence rates of childhood central nervous system tumors is controversial. Because growth hormone has the ability to increase cell proliferation, it is recommended that hGH therapy wait until central nervous system lesions are inactive and antitumor therapy complete, usually 1 to 2 years. CLINICAL PRESENTATION: We report the enlargement and decrease in size of a hypothalamic pilocytic astrocytoma in a 12-year-old boy after two trials of hGH. Partial resection and radiation of the tumor were performed at 3 years of age, with no change noted over the next 9 years. His height was less than the 5th centile with midparental height at the 90th to 95th centiles. Growth velocity was 3.3 cm/yr. Bone age was normal and there were no signs of puberty. There was no GH response to clonidine and L-dopa testing. INTERVENTION: Volume measurements were performed on gadolinium enhanced tumor images. Growth rate increased to 11.7 cm and the tumor volume increased 230{\%} over the 12 months of hGH therapy. Significant tumor shrinkage (42{\%}) and growth deceleration occurred within the 3 month interval of stopping hGH. Tumor volume again increased (134{\%}) and decreased (22{\%}) after restarting and then stopping hGH. No evidence of tumor necrosis or alteration in ventricular size was found. The patient was asymptomatic. CONCLUSION: These observations indicate that tumor size change is associated with the metabolic response to hGH therapy. It is unclear whether the volume increase represents altered blood-brain or selective blood-tumor barrier permeability, growth factor receptors, and/or tumor cell growth.",
keywords = "Astrocytoma, Growth, Growth hormone, Magnetic resonance imaging, Tumor growth",
author = "Connors, {Matthew H.} and Boggan, {James E.} and Brian Chong and Sobha Kollipara",
year = "1996",
month = "12",
doi = "10.1097/00006123-199612000-00037",
language = "English (US)",
volume = "39",
pages = "1243--1246",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Expansion and shrinkage of central nervous system tumor coinciding with human growth hormone therapy

T2 - Case report

AU - Connors, Matthew H.

AU - Boggan, James E.

AU - Chong, Brian

AU - Kollipara, Sobha

PY - 1996/12

Y1 - 1996/12

N2 - OBJECTIVE AND IMPORTANCE: The influence of human growth hormone (hGH) therapy on the recurrence rates of childhood central nervous system tumors is controversial. Because growth hormone has the ability to increase cell proliferation, it is recommended that hGH therapy wait until central nervous system lesions are inactive and antitumor therapy complete, usually 1 to 2 years. CLINICAL PRESENTATION: We report the enlargement and decrease in size of a hypothalamic pilocytic astrocytoma in a 12-year-old boy after two trials of hGH. Partial resection and radiation of the tumor were performed at 3 years of age, with no change noted over the next 9 years. His height was less than the 5th centile with midparental height at the 90th to 95th centiles. Growth velocity was 3.3 cm/yr. Bone age was normal and there were no signs of puberty. There was no GH response to clonidine and L-dopa testing. INTERVENTION: Volume measurements were performed on gadolinium enhanced tumor images. Growth rate increased to 11.7 cm and the tumor volume increased 230% over the 12 months of hGH therapy. Significant tumor shrinkage (42%) and growth deceleration occurred within the 3 month interval of stopping hGH. Tumor volume again increased (134%) and decreased (22%) after restarting and then stopping hGH. No evidence of tumor necrosis or alteration in ventricular size was found. The patient was asymptomatic. CONCLUSION: These observations indicate that tumor size change is associated with the metabolic response to hGH therapy. It is unclear whether the volume increase represents altered blood-brain or selective blood-tumor barrier permeability, growth factor receptors, and/or tumor cell growth.

AB - OBJECTIVE AND IMPORTANCE: The influence of human growth hormone (hGH) therapy on the recurrence rates of childhood central nervous system tumors is controversial. Because growth hormone has the ability to increase cell proliferation, it is recommended that hGH therapy wait until central nervous system lesions are inactive and antitumor therapy complete, usually 1 to 2 years. CLINICAL PRESENTATION: We report the enlargement and decrease in size of a hypothalamic pilocytic astrocytoma in a 12-year-old boy after two trials of hGH. Partial resection and radiation of the tumor were performed at 3 years of age, with no change noted over the next 9 years. His height was less than the 5th centile with midparental height at the 90th to 95th centiles. Growth velocity was 3.3 cm/yr. Bone age was normal and there were no signs of puberty. There was no GH response to clonidine and L-dopa testing. INTERVENTION: Volume measurements were performed on gadolinium enhanced tumor images. Growth rate increased to 11.7 cm and the tumor volume increased 230% over the 12 months of hGH therapy. Significant tumor shrinkage (42%) and growth deceleration occurred within the 3 month interval of stopping hGH. Tumor volume again increased (134%) and decreased (22%) after restarting and then stopping hGH. No evidence of tumor necrosis or alteration in ventricular size was found. The patient was asymptomatic. CONCLUSION: These observations indicate that tumor size change is associated with the metabolic response to hGH therapy. It is unclear whether the volume increase represents altered blood-brain or selective blood-tumor barrier permeability, growth factor receptors, and/or tumor cell growth.

KW - Astrocytoma

KW - Growth

KW - Growth hormone

KW - Magnetic resonance imaging

KW - Tumor growth

UR - http://www.scopus.com/inward/record.url?scp=0029948316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029948316&partnerID=8YFLogxK

U2 - 10.1097/00006123-199612000-00037

DO - 10.1097/00006123-199612000-00037

M3 - Article

C2 - 8938782

AN - SCOPUS:0029948316

VL - 39

SP - 1243

EP - 1246

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 6

ER -